Mendus

.Hero-module--bg-image--629a6.gbi--1219487161-tmVTQyyNHGLkkwxFGyRKW9:before { opacity: 1; background-image: url('/static/6d9b87783341ce51e45ef11f598677aa/6f033/Investors_1-1-scaled.jpg'); }

Att förändra hur cancer behandlasVi utforskar hur kraften i kroppens immunsystem kan användas för att förbättra långtidsöverlevnaden för cancerpatienter, samtidigt som hälsan och livskvaliteten bevaras.
Om oss
<picture><source type="image/webp" srcSet="/static/f8f43a64a4167819477f905df0ef8f15/20e94/251002-SWE.webp 146w,/static/f8f43a64a4167819477f905df0ef8f15/8079e/251002-SWE.webp 291w,/static/f8f43a64a4167819477f905df0ef8f15/5224f/251002-SWE.webp 582w" sizes="(min-width: 582px) 582px, 100vw"/><img data-gatsby-image-ssr="" data-main-image="" style="opacity:0" sizes="(min-width: 582px) 582px, 100vw" decoding="async" loading="lazy" src="/static/f8f43a64a4167819477f905df0ef8f15/17290/251002-SWE.png" srcSet="/static/f8f43a64a4167819477f905df0ef8f15/07392/251002-SWE.png 146w,/static/f8f43a64a4167819477f905df0ef8f15/b73ca/251002-SWE.png 291w,/static/f8f43a64a4167819477f905df0ef8f15/17290/251002-SWE.png 582w" alt=""/></picture>
PressmeddelandeLäs mer
Intervju
<picture><source type="image/webp" srcSet="/static/3bf5d9a2043ea12a69d4fe6cc8971382/c690a/251121-BTG-4.webp 529w,/static/3bf5d9a2043ea12a69d4fe6cc8971382/7f271/251121-BTG-4.webp 1058w,/static/3bf5d9a2043ea12a69d4fe6cc8971382/1404b/251121-BTG-4.webp 2116w" sizes="(min-width: 2116px) 2116px, 100vw"/><img data-gatsby-image-ssr="" data-main-image="" style="opacity:0" sizes="(min-width: 2116px) 2116px, 100vw" decoding="async" loading="lazy" src="/static/3bf5d9a2043ea12a69d4fe6cc8971382/4ea1d/251121-BTG-4.jpg" srcSet="/static/3bf5d9a2043ea12a69d4fe6cc8971382/8abc6/251121-BTG-4.jpg 529w,/static/3bf5d9a2043ea12a69d4fe6cc8971382/25568/251121-BTG-4.jpg 1058w,/static/3bf5d9a2043ea12a69d4fe6cc8971382/4ea1d/251121-BTG-4.jpg 2116w" alt=""/></picture>
Fokus på Mendus Q3 2025-rapport: Bjørn-Tore GjertsenLäs intervjun
<picture><source type="image/webp" srcSet="/static/748d7dabaf87d868eb9b202a8d5e9257/f47e3/251119-directed-share-issue-SWE-e1763544214797.webp 194w,/static/748d7dabaf87d868eb9b202a8d5e9257/9109e/251119-directed-share-issue-SWE-e1763544214797.webp 388w,/static/748d7dabaf87d868eb9b202a8d5e9257/88930/251119-directed-share-issue-SWE-e1763544214797.webp 776w" sizes="(min-width: 776px) 776px, 100vw"/><img data-gatsby-image-ssr="" data-main-image="" style="opacity:0" sizes="(min-width: 776px) 776px, 100vw" decoding="async" loading="lazy" src="/static/748d7dabaf87d868eb9b202a8d5e9257/a3492/251119-directed-share-issue-SWE-e1763544214797.jpg" srcSet="/static/748d7dabaf87d868eb9b202a8d5e9257/f0b5b/251119-directed-share-issue-SWE-e1763544214797.jpg 194w,/static/748d7dabaf87d868eb9b202a8d5e9257/2ff7f/251119-directed-share-issue-SWE-e1763544214797.jpg 388w,/static/748d7dabaf87d868eb9b202a8d5e9257/a3492/251119-directed-share-issue-SWE-e1763544214797.jpg 776w" alt=""/></picture>
 Läs mer
<picture><source type="image/webp" srcSet="/static/efa4a3fec787a32936aebc05374bcaed/ee1b5/251113-Q32025-SWE.webp 243w,/static/efa4a3fec787a32936aebc05374bcaed/a7a97/251113-Q32025-SWE.webp 486w,/static/efa4a3fec787a32936aebc05374bcaed/061ee/251113-Q32025-SWE.webp 972w" sizes="(min-width: 972px) 972px, 100vw"/><img data-gatsby-image-ssr="" data-main-image="" style="opacity:0" sizes="(min-width: 972px) 972px, 100vw" decoding="async" loading="lazy" src="/static/efa4a3fec787a32936aebc05374bcaed/07147/251113-Q32025-SWE.jpg" srcSet="/static/efa4a3fec787a32936aebc05374bcaed/e5637/251113-Q32025-SWE.jpg 243w,/static/efa4a3fec787a32936aebc05374bcaed/075d0/251113-Q32025-SWE.jpg 486w,/static/efa4a3fec787a32936aebc05374bcaed/07147/251113-Q32025-SWE.jpg 972w" alt=""/></picture>
Mendus publicerar Q3-rapportLäs mer
VD har ordet
<picture><source type="image/webp" srcSet="/static/42c1083d017d2cbf604bc69ab84b4f71/19d81/Manting_banner_headspace-1-scaled-e1746523367733.webp 442w,/static/42c1083d017d2cbf604bc69ab84b4f71/42a33/Manting_banner_headspace-1-scaled-e1746523367733.webp 883w,/static/42c1083d017d2cbf604bc69ab84b4f71/30950/Manting_banner_headspace-1-scaled-e1746523367733.webp 1766w" sizes="(min-width: 1766px) 1766px, 100vw"/><img data-gatsby-image-ssr="" data-main-image="" style="opacity:0" sizes="(min-width: 1766px) 1766px, 100vw" decoding="async" loading="lazy" src="/static/42c1083d017d2cbf604bc69ab84b4f71/529ef/Manting_banner_headspace-1-scaled-e1746523367733.jpg" srcSet="/static/42c1083d017d2cbf604bc69ab84b4f71/96280/Manting_banner_headspace-1-scaled-e1746523367733.jpg 442w,/static/42c1083d017d2cbf604bc69ab84b4f71/3ff14/Manting_banner_headspace-1-scaled-e1746523367733.jpg 883w,/static/42c1083d017d2cbf604bc69ab84b4f71/529ef/Manting_banner_headspace-1-scaled-e1746523367733.jpg 1766w" alt=""/></picture>
Uppdaterad klinisk utvecklingsstrategi baserad på positiva dataLäs mer
<picture><source type="image/webp" srcSet="/static/f8f43a64a4167819477f905df0ef8f15/20e94/251002-SWE.webp 146w,/static/f8f43a64a4167819477f905df0ef8f15/8079e/251002-SWE.webp 291w,/static/f8f43a64a4167819477f905df0ef8f15/5224f/251002-SWE.webp 582w" sizes="(min-width: 582px) 582px, 100vw"/><img data-gatsby-image-ssr="" data-main-image="" style="opacity:0" sizes="(min-width: 582px) 582px, 100vw" decoding="async" loading="lazy" src="/static/f8f43a64a4167819477f905df0ef8f15/17290/251002-SWE.png" srcSet="/static/f8f43a64a4167819477f905df0ef8f15/07392/251002-SWE.png 146w,/static/f8f43a64a4167819477f905df0ef8f15/b73ca/251002-SWE.png 291w,/static/f8f43a64a4167819477f905df0ef8f15/17290/251002-SWE.png 582w" alt=""/></picture>
PressmeddelandeLäs mer
Intervju
<picture><source type="image/webp" srcSet="/static/3bf5d9a2043ea12a69d4fe6cc8971382/c690a/251121-BTG-4.webp 529w,/static/3bf5d9a2043ea12a69d4fe6cc8971382/7f271/251121-BTG-4.webp 1058w,/static/3bf5d9a2043ea12a69d4fe6cc8971382/1404b/251121-BTG-4.webp 2116w" sizes="(min-width: 2116px) 2116px, 100vw"/><img data-gatsby-image-ssr="" data-main-image="" style="opacity:0" sizes="(min-width: 2116px) 2116px, 100vw" decoding="async" loading="lazy" src="/static/3bf5d9a2043ea12a69d4fe6cc8971382/4ea1d/251121-BTG-4.jpg" srcSet="/static/3bf5d9a2043ea12a69d4fe6cc8971382/8abc6/251121-BTG-4.jpg 529w,/static/3bf5d9a2043ea12a69d4fe6cc8971382/25568/251121-BTG-4.jpg 1058w,/static/3bf5d9a2043ea12a69d4fe6cc8971382/4ea1d/251121-BTG-4.jpg 2116w" alt=""/></picture>
Fokus på Mendus Q3 2025-rapport: Bjørn-Tore GjertsenLäs intervjun

<picture><source type="image/webp" srcSet="/static/8fbb9182e4eaf95a3da736b2a3ebdc7e/d7070/Startpage_1-NEW.webp 240w,/static/8fbb9182e4eaf95a3da736b2a3ebdc7e/4ce17/Startpage_1-NEW.webp 480w,/static/8fbb9182e4eaf95a3da736b2a3ebdc7e/95cd0/Startpage_1-NEW.webp 960w" sizes="(min-width: 960px) 960px, 100vw"/><img data-gatsby-image-ssr="" data-main-image="" style="opacity:0" sizes="(min-width: 960px) 960px, 100vw" decoding="async" loading="lazy" src="/static/8fbb9182e4eaf95a3da736b2a3ebdc7e/49439/Startpage_1-NEW.jpg" srcSet="/static/8fbb9182e4eaf95a3da736b2a3ebdc7e/ff13b/Startpage_1-NEW.jpg 240w,/static/8fbb9182e4eaf95a3da736b2a3ebdc7e/28e6b/Startpage_1-NEW.jpg 480w,/static/8fbb9182e4eaf95a3da736b2a3ebdc7e/49439/Startpage_1-NEW.jpg 960w" alt=""/></picture>
Att få övertagetIdag är återkommande tumörer den främsta orsaken till cancerrelaterade dödsfall. Vi strävar efter att minska tumöråterfall genom att utnyttja immunsystemet för att agera mot kvarvarande cancerceller.
Hur vi gör

<picture><source type="image/webp" srcSet="/static/bfd9bafcd3660b03f3b72edb150264f7/ecbb3/Startpage_2-1.webp 450w,/static/bfd9bafcd3660b03f3b72edb150264f7/10d3d/Startpage_2-1.webp 900w,/static/bfd9bafcd3660b03f3b72edb150264f7/7d31d/Startpage_2-1.webp 1800w" sizes="(min-width: 1800px) 1800px, 100vw"/><img data-gatsby-image-ssr="" data-main-image="" style="opacity:0" sizes="(min-width: 1800px) 1800px, 100vw" decoding="async" loading="lazy" src="/static/bfd9bafcd3660b03f3b72edb150264f7/b37a5/Startpage_2-1.jpg" srcSet="/static/bfd9bafcd3660b03f3b72edb150264f7/ea40c/Startpage_2-1.jpg 450w,/static/bfd9bafcd3660b03f3b72edb150264f7/a3b1e/Startpage_2-1.jpg 900w,/static/bfd9bafcd3660b03f3b72edb150264f7/b37a5/Startpage_2-1.jpg 1800w" alt="&lt;p&gt;Two chemistry laboratory researchers, a young man and a young woman working together in a biology, chemistry research laboratory.= in a university. Focus on the laboratory equipment with the personnel in the background. Photographed in horizontal format.&lt;/p&gt;
"/></picture>
Nya sätt att göra skillnadVi tillämpar vår förståelse av dendritisk cellbiologi för att designa immunterapier mot cancer som stimulerar aktiv immunitet, den enda långvariga formen av immunitet.
Om oss

<picture><source type="image/webp" srcSet="/static/0237bef387e76cffaa6681d16a2b59c4/8cdf4/Startpage_3-1.webp 302w,/static/0237bef387e76cffaa6681d16a2b59c4/39272/Startpage_3-1.webp 603w,/static/0237bef387e76cffaa6681d16a2b59c4/0d01b/Startpage_3-1.webp 1206w" sizes="(min-width: 1206px) 1206px, 100vw"/><img data-gatsby-image-ssr="" data-main-image="" style="opacity:0" sizes="(min-width: 1206px) 1206px, 100vw" decoding="async" loading="lazy" src="/static/0237bef387e76cffaa6681d16a2b59c4/e579d/Startpage_3-1.jpg" srcSet="/static/0237bef387e76cffaa6681d16a2b59c4/8f82e/Startpage_3-1.jpg 302w,/static/0237bef387e76cffaa6681d16a2b59c4/d2caf/Startpage_3-1.jpg 603w,/static/0237bef387e76cffaa6681d16a2b59c4/e579d/Startpage_3-1.jpg 1206w" alt="&lt;p&gt;Molecular Structure. Science background. 3D Render&lt;/p&gt;
"/></picture>
Investera i framtidens cancervårdMendus är noterat på NASDAQ Stockholm under tickersymbolen IMMU. Du hittar all relevant information om Mendus-aktien på vår investerarsida.
Investerare

Senaste nyheternaNyheter och Evenemang
Inga hittade artiklar

.FullWidthImage-module--bg-image-mobile--ba5fc.FullWidthImage-module--hide-in-mobile--9cd89.gbi--473978910-mezJ1YmEGgrY2rmu6jivsd:before { opacity: 1; background-image: url('/static/58920a993c01776af52e6d8a69a7452d/60e72/What-we-do_1-mobile.jpg'); }

Hur vi gör